The draft guidelines of the proposed new Bill released by the Department of Health and Family Welfare, proposes to insert a separate chapter on clinical trial, Chapter 4A in it. The Bill is expected to be placed before the Parliament for its approval during the Budget session.
"Any new drug or investigational new drug in contravention of section 4A and the rules made thereunder, shall be punishable with imprisonment which may extend to three years or fine which may extend to five lakh rupees or both.
The Drugs Control Officer or any other officer authorised by the Central Licensing Authority shall have the power to enter with or without prior notice into any premises related to clinical trial to inspect the facilities, record, data, documents, books, drugs including investigational new drugs, notified category of medical devices and cosmetics, it further said.
The proposed Bill also says that any company manufacturing cosmetic which is found to be adulterated or spurious would be punishable with imprisonment up to five years, besides fine not less than Rs two lakh or three times value of the cosmetics confiscated, whichever is more.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
